Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

NCT05270044 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

815

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Encorafenib and Binimetinib
DRUG: Placebo to match Encorafenib ; Placebo to match Binimetinib

Sponsor

Pierre Fabre Medicament

Collaborators

[object Object]